A leading University NHS Foundation Trust, based in the UK, is the study sponsor for a multi-site randomized 1-year evaluation of a pharmaceutical treatment for patients with cardiomyopathy.
A specialist healthtech company headquartered in Ukraine, who successfully developed a leading, cloud-based AI analysis platform, sought to expand their business model. Their goal was to create an end-to-end remote holter monitoring service for hospitals and clinics by incorporating clinical-grade wireless ECG devices.
A leading hospital group, based in Chennai, India approached LifeSignals in 2020 to introduce a wireless vital sign monitoring system for COVID-19 patients in numerous locations to help respond to the pandemic and save lives.
A health monitoring center based in New York, USA for at-home physicians and nursing oversight companies has been working with LifeSignals since 2018 to broaden their services to skilled nursing facilities.
In 2016, LifeSignals partnered with a company based in Kerala, India that is transforming the way ambulatory cardiac monitoring is delivered and become the new normal among the leading cardiologists and neurologists in hospitals across the country.
An ambitious AI healthcare technology company based in Hyderabad, India approached LifeSignals in 2019 to take healthcare closer to consumers by utilizing the power of cloud technology.
A telehealth and cardiac screening company headquartered in Manila has been working with LifeSignals as of early 2020 to expand remote cardiac monitoring in the Philippines.
A leading Independent Diagnostic Testing Facility (IDTF), providing ambulatory cardiac monitoring services headquartered in New York, USA, came to LifeSignals in 2019 in search of a reliable, affordable, and FDA approved wireless biosensor that accurately captured and transmitted multi-channel ECG, for a real-time MCT application.